Cartiva Synthetic Cartilage Implant
Centralized before Judge Kristine G. Baker in the Eastern District of Arkansas in February 2026, the Cartiva Synthetic Cartilage Implant litigation consolidates federal claims alleging that a synthetic cartilage implant device, typically used to treat arthritis in the big-toe joint, fails or degrades after implantation, causing pain and requiring revision surgery. With only 21 total actions filed as of the JPML's September 2026 report, this is among the youngest and smallest currently active federal MDLs, roughly seven months into its existence.
At this earliest stage, the structural questions that will define the litigation's path forward are still entirely open: no case-management order, leadership structure, or master complaint framework has had time to mature, and no general-causation record yet exists for the alleged device-failure mechanism. Duration risk is driven almost entirely by how quickly the court establishes an initial pretrial schedule and how many additional device-failure claims are filed or transferred in as awareness of the litigation and the underlying implant's performance history grows.
Implanted orthopedic-device litigation of this kind typically turns, once it matures, on whether the alleged failure reflects a design issue common to the device generally or a more individualized surgical or patient-specific factor — a distinction this docket has not yet had the opportunity to develop through discovery. Criterica Intelligence's platform tracks this kind of early-stage MDL formation across every active docket, providing a consistent structural read on a litigation's earliest development regardless of its eventual size, without projecting any causation finding for this or any individual implant claim.
Plaintiffs allege that the synthetic cartilage implant, typically used for big-toe joint arthritis, fails or degrades after implantation, causing pain and requiring revision surgery.
Very early — centralized in February 2026 with only 21 total actions filed as of the JPML's September 2026 report, and no case-management order, bellwether process, or general-causation record yet established.
How many additional device-failure claims are filed or transferred in as awareness of the litigation and the implant's performance history grows will be the key early indicator of the docket's eventual scale.
Whether the alleged implant failure reflects a design issue common to the device generally or a more individualized surgical or patient-specific factor — a question the docket has not yet developed through discovery.
Statistics shown reflect historical or illustrative model outputs derived from real case data. They are not predictions or guarantees of any individual outcome. Litigation results depend on facts, jurisdiction, judge, and counsel, and vary case by case. Model accuracy is subject to selection effects and changing legal dynamics.